Viridian Therapeutics, Inc.\DE (VRDN) company profile
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
About Viridian Therapeutics, Inc.\DE
Pharmaceutical Preparations, SIC 2834
This biopharmaceutical company focuses on discovering, developing, and commercializing targeted therapies for serious autoimmune and rare conditions. Its research and clinical pipeline centers on therapeutic candidates addressing validated biological pathways, notably thyroid eye disease and related autoimmune indications. The company's core development programs feature anti-insulin-like growth factor 1 receptor product candidates, including the intravenous monoclonal antibody veligrotug and subcutaneous elegrobart. In addition, its pipeline includes neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008, alongside a thyroid-stimulating hormone receptor inhibitor program. Its end users are patients suffering from debilitating rare diseases, with commercial outreach targeting physicians and healthcare payors.
The business manages global clinical programs across international study locations, including trials throughout the United States. It maintains worldwide commercial rights for its leading product candidates, excluding Japan and greater China, where commercialization and development rights have been out-licensed to regional corporate partners. The provided excerpt does not state the company's headquarters location.
Summary of the business section of Viridian Therapeutics, Inc.\DE's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Viridian Therapeutics, Inc.\DE
- Headquarters
- Waltham, MA
- Address
- 221 Crescent Street, Suite 103a 02453
- Phone
- (617) 272-4600
- Website
- viridiantherapeutics.com
- Employees
- 252, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VRDN
- Former tickers
- MGEN until Jan 20, 2021; SGNL until Mar 24, 2017
- Exchange
- Nasdaq
- IPO date
- Jun 19, 2014
- Shares outstanding
- 113M, Aug 3, 2026
- Public float
- $943.00M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-15 reverse, Mar 26, 2021; 1-for-15 reverse, Nov 13, 2020; 1-for-15 reverse, Mar 24, 2017; 1-for-15 reverse, Nov 7, 2016; 1-for-13 reverse, Mar 27, 2015
- SEC CIK
- 1590750
- CUSIP
- 92790C104
- ISIN
- US92790C1045
- FIGI
- BBG002H242Z5
- Share class FIGI
- BBG002H24301
- LEI
- 549300C775BNYF550E70
- EIN
- 47-1187261
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen F. Mahoney | President and CEO, Director | 33,349 |
| Jennifer Tousignant | Chief Legal Officer | 0 |
| Radhika Tripuraneni | Chief Medical Officer | 40,000 |
| Seth Harmon | Chief Financial Officer | 7,850 |
| Thomas W. Beetham | Chief Operating Officer | 13,361 |
| Jennifer K. Moses | Director | – |
| Sarah Gheuens | Director | – |
| Jeffrey Robert Ajer | Director | – |
| Tomas Kiselak | Director | – |
| Arlene Morris | Director | – |
| Christopher W. Cain | Director | – |
| Funds Management LLC Fairmount | Director | 3,459,913 |
| Healthcare Fund II GP LLC Fairmount | Director | 3,914,458 |
| Healthcare Fund II L.P. Fairmount | Director | 5,090,928 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.78M | $18.85M | $3.21M | $189 | $125 |
| FY2024 | $1.12M | -$2.05M | $2.05M | $117 | $93 |
| FY2023 Dr Violin | $2.21M | -$744.99K | $5.65M | $132 | $94 |
| FY2023 Mr Mahoney | $12.48M | $22.38M | $5.65M | $132 | $94 |
| FY2023 Mr Myers | $36.41M | $6.25M | $5.65M | $132 | $94 |
| FY2022 | $4.65M | $7.62M | $2.07M | $178 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Stephen Mahoney Chief Executive Officer | $700.00K | – | $1.06M | $4.38M | $630.00K | $6.44K | $6.78M | +506% |
| Seth Harmon Chief Financial Officer | $480.00K | – | $361.23K | $1.50M | $288.00K | $17.65K | $2.64M | +243% |
| Jennifer Tousignant Chief Legal Officer | $469.91K | $50.00K | $297.99K | $1.23M | $281.95K | $18.09K | $2.35M | -52% |
| Thomas Beetham Chief Operating Officer | $545.00K | – | $542.34K | $2.25M | $408.75K | $19.23K | $3.76M | +365% |
| Radhika Tripuraneni | $430.64K | $50.00K | – | $3.34M | $253.53K | $4.89K | $4.08M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 19, 2014
- Offer price
- $10.00
- Securities offered
- 850,000
- Gross proceeds
- $8.50M
- Exchange
- Nasdaq
- First trading day
- Jun 18, 2014
- First-day close
- $9.09-9.1%
- Lock-up ends (est.)
- Dec 15, 2014
“Per Share Total Public offering price $ 10.00 $ 8,500,000 Underwriting discounts and commissions (1) $ 0.70 $ 595,000 Proceeds, before expenses, to us $ 9.30 $ 7,905,000 (1) The underwriters will receive compensation in addition to the underwriting discount.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 252 full-time employees located in the U.S., including at our facilities in Waltham, Massachusetts and Boulder, Colorado.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?